TOX Gene: a Novel Target for Human Cancer Gene Therapy

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2016 Feb 18

PMID 26885442

Citations 20

Authors

Xin Yu

Zheng Li

Affiliations

Soon will be listed here.

Abstract

Thymocyte selection-associated high mobility group box factor (TOX) is a member of an evolutionarily conserved DNA-binding protein family and is expressed in several immune-relevant cell subsets. TOX encodes a nuclear protein of the high-mobility group box superfamily. It contains a DNA-binding domain, which allows it to regulate transcription by modifying local chromatin structure and modulating the formation of multi-protein complexes. Previous studies have shown that TOX play important roles in immune system. More recently, several studies have described TOX expression is frequently upregulated in diverse types of human tumors and the overregulation often associates with tumor progression. Moreover, TOXis involved in the control of cell apoptosis, growth, metastasis, DNA repair and so on. In this review, we provide an overview of current knowledge concerning the role of TOX in tumor development and progression biology function. To our knowledge, this is the first review about the role of thisnew oncogene in tumor development and progression.

Citing Articles

Low expression of TOX predicts poor prognosis of patients with breast cancer in the real world: A retrospective study.

Tan C, Wu D, Yang X, Zhang S, Liu S, Yu B Heliyon. 2025; 11(1):e41180.

PMID: 39758401 PMC: 11699305. DOI: 10.1016/j.heliyon.2024.e41180.

Transcriptomic and intervention evidence reveals domestic dogs as a promising model for anti-inflammatory investigation.

Zeng M, Zhou T, Li Z, Li G, Zhang S, Wang L Aging Cell. 2024; 23(5):e14127.

PMID: 38426629 PMC: 11113267. DOI: 10.1111/acel.14127.

Single-cell ATAC sequencing identifies sleepy macrophages during reciprocity of cytokines in infection.

Khandibharad S, Singh S Microbiol Spectr. 2024; 12(3):e0347823.

PMID: 38299832 PMC: 10913457. DOI: 10.1128/spectrum.03478-23.

Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities.

Brunell A, Lahesmaa R, Autio A, Thotakura A Front Immunol. 2023; 14:1151632.

PMID: 37122741 PMC: 10140554. DOI: 10.3389/fimmu.2023.1151632.

Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.

Huang L, Liu X, Li L, Wang L, Wu N, Liu Z Med Oncol. 2022; 39(5):92.

PMID: 35568771 DOI: 10.1007/s12032-022-01690-3.

References

Constantinides M, McDonald B, Verhoef P, Bendelac A . A committed precursor to innate lymphoid cells. Nature. 2014; 508(7496):397-401. PMC: 4003507. DOI: 10.1038/nature13047. View

Tessema M, Yingling C, Grimes M, Thomas C, Liu Y, Leng S . Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. PLoS One. 2012; 7(4):e34850. PMC: 3319602. DOI: 10.1371/journal.pone.0034850. View

Bayraktar S, Thompson P, Yoo S, Do K, Sahin A, Arun B . The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013; 18(5):493-500. PMC: 3662839. DOI: 10.1634/theoncologist.2012-0419. View

Weidhaas J . Using microRNAs to understand cancer biology. Lancet Oncol. 2009; 11(2):106-7. PMC: 5919278. DOI: 10.1016/S1470-2045(09)70386-9. View

Zhang Y, Wang Y, Yu R, Huang Y, Su M, Xiao C . Molecular markers of early-stage mycosis fungoides. J Invest Dermatol. 2012; 132(6):1698-706. DOI: 10.1038/jid.2012.13. View

Easton D, Pooley K, Dunning A, Pharoah P, Thompson D, Ballinger D . Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-93. PMC: 2714974. DOI: 10.1038/nature05887. View

Yun S, Lee S, Yoon S, Kim M, Piao Z, Myung P . TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. Immunol Lett. 2010; 136(1):29-36. DOI: 10.1016/j.imlet.2010.11.008. View

Chen M, Wu X, Shen W, Wei M, Li C, Cai B . Association between polymorphisms of trinucleotide repeat containing 9 gene and breast cancer risk: evidence from 62,005 subjects. Breast Cancer Res Treat. 2010; 126(1):177-83. DOI: 10.1007/s10549-010-1114-6. View

Willemze R, Jaffe E, Burg G, Cerroni L, Berti E, Swerdlow S . WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10):3768-85. DOI: 10.1182/blood-2004-09-3502. View

10.

Huang Y, Litvinov I, Wang Y, Su M, Tu P, Jiang X . Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis. Oncotarget. 2014; 5(12):4418-25. PMC: 4147334. DOI: 10.18632/oncotarget.2031. View

11.

Goll M, Bestor T . Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005; 74:481-514. DOI: 10.1146/annurev.biochem.74.010904.153721. View

12.

Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y . Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One. 2008; 3(4):e2079. PMC: 2323612. DOI: 10.1371/journal.pone.0002079. View

13.

Ferreri A, Reni M . Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2007; 63(3):257-68. DOI: 10.1016/j.critrevonc.2007.04.012. View

14.

Riaz M, Berns E, Sieuwerts A, Ruigrok-Ritstier K, de Weerd V, Groenewoud A . Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. Breast Cancer Res Treat. 2011; 133(3):843-51. DOI: 10.1007/s10549-011-1663-3. View

15.

Mohile N, Abrey L . Primary central nervous system lymphoma. Semin Radiat Oncol. 2007; 17(3):223-9. DOI: 10.1016/j.semradonc.2007.02.008. View

16.

Morimura S, Sugaya M, Suga H, Miyagaki T, Ohmatsu H, Fujita H . TOX expression in different subtypes of cutaneous lymphoma. Arch Dermatol Res. 2014; 306(9):843-9. DOI: 10.1007/s00403-014-1501-7. View

17.

Wheeler S, Shi H, Lin F, Dasari S, Bednash J, Thorne S . Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models. Head Neck. 2013; 36(3):385-92. PMC: 4111913. DOI: 10.1002/hed.23312. View

18.

Veron A, Blein S, Cox D . Genome-wide association studies and the clinic: a focus on breast cancer. Biomark Med. 2014; 8(2):287-96. DOI: 10.2217/bmm.13.121. View

19.

Elematore I, Gonzalez-Hormazabal P, Reyes J, Blanco R, Bravo T, Peralta O . Association of genetic variants at TOX3, 2q35 and 8q24 with the risk of familial and early-onset breast cancer in a South-American population. Mol Biol Rep. 2014; 41(6):3715-22. DOI: 10.1007/s11033-014-3236-0. View

20.

McGirt L, Adams C, Baerenwald D, Zwerner J, Zic J, Eischen C . miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J Invest Dermatol. 2013; 134(4):1101-1107. PMC: 3961555. DOI: 10.1038/jid.2013.461. View